United Health Products, Inc 8-K, filed Nov 6, 2024
United Health Products, Inc. (UEEC)
About this 8-K
United Health Products, Inc filed this 8-K on November 6, 2024, reporting on events of November 4, 2024.
Items reported
- Item 8.01: Other events
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter) |
|
| |||
(State or other jurisdiction of incorporation) |
| (Commission File Number) |
| (IRS Employer Identification No.) |
(Address of Principal Executive Offices) (Zip Code) |
(
Registrant’s telephone number, including area code
___________________________________________________
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging Growth Company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
| Trading Symbol(s) |
| Name of each exchange on which registered |
N/A |
| N/A |
| N/A |
Item 8.01. Other Events.
On November 4, 2024, the United Health Products, Inc. issued a press release announcing an update on the FDA’s Premarket Approval application for the company’s HemoStyp® Gauze.
A copy of the press release is attached as Exhibit 99.1 and is incorporated herein by reference.
We refer you to the risk factors in Part II Item 1A of the company’s Quarterly Report on Form 10-Q for the period ended June 30, 2024 for a discussion of the risks relating to our Premarket Approval application.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit Number | Description | |
|
|
|
| ||
104 |
| Cover Page Interactive Data File (embedded within the Inline XBRL Document) |
| 2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.
United Health Products, Inc. |
| ||
| |||
Dated: November 6, 2024 | By: | /s/ Brian Thom | |
| Brian Thom Chief Executive Officer | ||
| 3 |
EXHIBIT 99.1
United Health Products Provides Update on FDA PMA Application
Mount Laurel, New Jersey – November 4, 2024 – United Health Products, Inc. (OTCPK: UEEC) today provided an update on the company’s FDA Premarket Approval (PMA) application process.
Following the company’s August 15, 2024 submission of its Submission Issue Request (SIR) to the FDA which responded to certain questions in the FDA’s June 18 letter and described the company’s approach to addressing certain FDA-identified deficiencies in its PMA application, the company held a videoconference with the FDA on October 29. The purpose of the meeting was to present, discuss and seek feedback from the FDA on the company’s proposed resolutions to the deficiencies. Topics discussed include the company’s clinical testing (including the results of its human trial), biocompatibility, product sterilization and shelf life. This meeting has provided the company with certainty on how to address the deficiencies, with many of the issues already having been resolved.
During the discussion, the company noted the results of its clinical trial involving 232 patients (of whom 118 were treated with its hemostatic gauze) that showed both non-inferiority and superiority for time to hemostasis using CelluSTAT (fka HemoStyp) relative to the standard of care and showed no evidence of heterogeneity of results across procedure categories, surgeons, or clinical sites, indicating both poolability and generalizability of study results. UHP also noted that none of the adverse events that occurred during the study were attributable to its hemostatic gauze product.
Notwithstanding the statistical conclusions of the clinical trial results, the FDA would like to see more data to confirm the safety and effectiveness of CelluSTAT in surgical procedures in the intestinal and thoracic organ space, where organ movement can impact the postoperative stability of a hemostat and where observation of postoperative rebleeding is more difficult. To address this concern, UHP has proposed to enroll a limited number of human subjects in a multi-site study as an extension of the original pivotal study, with patients undergoing surgical procedures within the organ space. Separately, the FDA confirmed that its earlier stated concern regarding use of CelluSTAT in vascular graft procedures had been adequately addressed.
UHP’s Chief Executive, Brian Thom, commented: “While we are pleased to confirm the path to resolving the list of deficiencies in our PMA application, we are disappointed that the strong results of our pivotal study and low incidence of adverse events were not sufficient to address the FDA’s specific concern regarding organ space applications of our device. The company will devote its resources to completing these additional surgical procedures efficiently and is confident that the results will reinforce the results of the existing study.”
The supplemental study process will consist of submitting an Investigational Device Exemption (IDE) for FDA approval, recruiting a contract research organization to assist in data collection and monitoring, evaluating and selecting 3-5 suitable sites for the surgical procedures, patient enrollment and follow up, and data processing and analysis. The company anticipates that this process will take approximately 6-7 months to complete. During this period, UHP expects to complete certain additional biocompatibility and sterility testing that was agreed to with the FDA to address other remaining deficiencies. The FDA’s 180-day application review period, of which approximately 90 days have elapsed, remains paused until the company submits responses to all deficiencies.
| 1 |
Brian Thom commented further: “Much progress has been made since submitting our PMA application in March. The FDA, through its Bioresearch Monitoring program (BIMO) has conducted two site inspections to review our pivotal study procedures and data integrity. And last week’s SIR meeting provided clarity on the limited list of tasks that remain. While we would have preferred to conduct any additional surgical testing under a post-approval study protocol, we respect the FDA’s concerns over patient safety and acknowledge the risks associated with hemostatic products such as ours. While a PMA cannot be assured, we have never been more optimistic regarding the outcome of this application process.”
About United Health Products -- UHP has developed and patented a Neutralized Regenerated Cellulose hemostatic agent. CelluSTAT is an all-natural product designed to control mild to moderate bleeding. UHP is seeking approval to access the human surgical market.
For more information on UHP visit the company’s new website: www.uhpcorp.com or contact the company at info@uhpcorp.com.
The company can also be reached by phone or text message at 475.755.1005.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements.
| 2 |